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Abstract
Therapeutic use of an unauthorised drug (or of an authorised drug for an unauthorised indication) for patients with
a life-threating disease is permitted outside a clinical trial as an Expanded Access Programme (EAP).
The regulations regarding EAPs is not the same all over the world. For example, the recommendation of the
European Medicines Agency (EMA) in EU countries also includes within EAPs patients who have been treated in a
clinical trial and who wish to continue the treatment. Nevertheless, the patients treated in a clinical trial could have
the option of continuing treatment for an extended period in an Open-label Extension study, aimed to generate
long-term data on efficacy, safety, tolerability and administration.
The aims of this paper – based on the difficulties and incoherence encountered by an Italian Ethic Committee (EC)
during the authorisation process of EAPs – are: understanding the origin of this misclassification by analysing
differences and similarities among USA, European and Italian regulations concerning EAPs; and showing difficulties
in classifying international study protocols as a consequence of the lack of harmonisation of definitions.
We performed a critical review of the current USA, European and Italian regulations and we analysed some practical
cases by retrieving protocols from Clinicaltrials.gov and the Italian Clinical Trials Registry (OsSC) containing in the
title the keywords ‘Expanded Access Programme’, “’Expanded Access’, ‘Open-label Extension study’ or ‘Early Access’.
We observed that the Food and Drug Administration ( FDA) definition of EAP is very clear while the EMA definition
is similar to that of an Open-label Extension study. This lack of a clear definition generates misclassification and it is
possible to find an EAP with an efficacy or safety endpoint; or an EAP managed as a clinical trial; or an EAP
classified in Clinical Trials Registries as a phase II, III or IV clinical trial.
The internationalisation of the studies requires a harmonisation on a global level of legislation and definitions to
eliminate misclassification of protocols. For this reason, the authors suggest that: a) the EMA definition should be
harmonised with the FDA definition of EAPs, b) European regulation, even if optional, should be adopted in a
compulsory way by national regulations. Moreover, separate registries for both EAPs and clinical trials should be
organised.
Keywords: Expanded access programme, Compassionate use programme, Open-label extension study, Early access
programme, Clinical trial
Background
Drugs are generally used according to their authorised
indications by the competent authorities. However,
there are situations where the use of an unauthorised
drug, or intentional use of an authorised drug for a
medical purpose not in accordance with the authorised
product information (off-label use), is regulated and
permitted, in clinical trials as well as in clinical prac-
tice. In a clinical trial, patients with therapeutic alter-
natives may decide whether or not to be treated with a
drug whose safety and efficacy is still uncertain. In
clinical practice, the use of an off-label drug is allowed
when a patient does not have therapeutic alternatives.
If patients have a life-threating disease or condition, the
therapeutic use of an unauthorised drug (or of an
authorised drug for an unauthorised indication) is permit-
ted outside a clinical trial in an Expanded Access
Programme (EAP).
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According to the Code of Federal Regulation (CFR) of
the Food and Drug Administration (FDA) EAPs, some-
times also called Compassionate Use Programmes
(CUPs), are proposed when manufacturers make an in-
vestigational drug available for therapeutic use, outside a
clinical trial, to treat patients with a serious disease in
the absence of comparable or satisfactory alternative
therapeutic on-label drugs that cannot either participate
or have already participated in a clinical trial [1].
This definition of EAP is not the same all over the
world. For example, the recommendation of the European
Medicines Agency (EMA) is for EU countries to include
within EAPs patients who have been treated in a clinical
trial and who wish to continue the treatment [2]. How-
ever, it is recognised worldwide that patients treated in a
clinical trial could have the option of continuing treatment
for an extended period in an Open-label Extension study
in order to generate long-term data on the intervention
efficacy, safety, tolerability and administration of the drug
[3, 4]. Furthermore, in contrast with the FDA, in Europe
CUPs and EAPs do not have the same meaning [1, 5].
The lack of a single shared definition, aims and com-
mon rules of the study protocols has already been re-
ported by the European Clinical Research Infrastructures
Network (ECRIN) [6]. A comprehensive survey on clin-
ical research regulatory requirements showed that 10
European countries, covering approximately 70 % of the
EU population, have adopted different requirements and
that ‘Compassionate Use’ is not managed in the same
way across Europe. For example, four of the ten
countries included in the study have no formal regulatory
system for this programme.
Today, international EAPs include patients from differ-
ent countries where the legal framework and definitions of
EAP are not the same. This calls for harmonisation, on a
global level, of legislation and definitions.
This paper is the result of difficulties and incoherence
encountered by an Italian Ethic Committee (EC) during
the authorisation process of EAPs [1, 2] to recognise the
coherence between the definition, aim and primary end-
point of study protocols presented as EAPs. This has im-
plications, for example, on the way the study is
conducted or also on the correctness of the information
to be provided to the patients.
To understand the causes and underline the conse-
quences of this incoherence, we have reviewed the
current USA, European and Italian regulations and we
have provided some case study examples.
Review
Methods
USA, European and Italian regulations and regulatory
procedures concerning EAPs were retrieved, read and
compared independently by two authors (IA, AL).
In August 2012, IA and AL retrieved and independ-
ently reviewed all studies with titles containing the key-
words: ‘Expanded Access’, ‘Expanded Access Programme’,
‘Open-label Extension study’ and ‘Early Access’ from the
Italian Clinical Trials Registry (OsSC) [7]. Only the stud-
ies recorded from January 2004 to June 2012 were con-
sidered because until 2004 there was no OsSC registry
and it has been provisionally closed since June 2012.
The term ‘Compassionate Use Programme’ was not in
the review because in the retrieved studies we did not
reveal incoherence between the aim and endpoints of
these programmes. In contrast with the FDA, in Europe
CUPs and EAPs do not have the same meaning [1, 5].
The European EAPs have coherence problems be-
tween aim and endpoint, because for EMA legislation,
adopted by Italian law, patients who have been treated
in a clinical trial and who wish to continue the treatment
can be included in an EAP [2]. As a consequence, some-
times European EAPs have the aims and endpoints of
Open-label Extension studies.
For the eligible studies we tabulated the following de-
tails: NCT code, EudraCT number, trial code, title, design
and number of arms, phase, investigational drug, thera-
peutic area, purpose, starting date, national/international
trial, primary and secondary endpoints and sponsor. We
also collected information about primary and secondary
endpoints and verified their coherence with the aim of
study protocol. The studies identified were then searched
for in the American Clinical Trials Registry [8] and ex-
tracted when available. NCT code, EudraCT number, trial
code and title were used to be sure that identified proto-
cols were the same.
We classified the studies in the following clusters:
 EAPs according to the FDA (Code of Federal
Regulation) [9], such as studies designed to ensure
that potentially life-saving investigational drugs are
available outside a clinical trial to patients with serious
or immediately life-threatening diseases for which
there is no comparable or satisfactory alternative
treatment options, or to patients who either cannot
participate or have already participated in a clinical
trial: e.g. those who are not eligible because they have
a different disease or stage of disease or otherwise do
not meet the enrolment criteria, or because enrolment
in the trial is closed, or because the trial site is not
geographically accessible, etc. The cluster of EAPs
included studies containing in the title the terms
Expanded Access and Expanded Access Programme
and Early Access
 Open-label Extension studies, according to the
definition of Chin and Taylor [3, 4], such as studies
following phase IIB or IIIA double-blind randomised
placebo-controlled trials where the participant has
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the option of remaining in the study in an open-
label fashion (i.e. they know which drug is being
used) for an extended period of time (sometimes
several years, often until the drug is licensed).
Patients may be informed of this opportunity before
or after the double-blind trial ends. Such studies
generate long-term data on the efficacy, safety,
tolerability and administration of the drug
 ‘Other’: studies that could not be univocally
included in the previous groups
We used the FDA definition of EAPs because it clearly
distinguishes the EAP from an Open-label Extension
study, whereas this is not clear at all in the European
and Italian regulations.
Descriptive statistics, mainly proportions, were used to
analyse all data collected. Data was collected and ana-
lysed using Microsoft Excel (Microsoft Inc., Redmond,
WA, USA).
Results
A matter of classification
The USA, EMA and Italian EAP regulations are com-
pared in Table 1.
In the United States, the investigational drug is avail-
able either through a clinical trial or through an EAP.
The EAP (sometimes also called CUP) is regulated by
Title 21 of the Code of Federal Regulations [1]. For the
FDA an EAP is a way to make potentially life-saving
drugs available to patients in certain serious circum-
stances or with immediately life-threatening diseases for
which there are no comparable or satisfactory alternative
treatment options. Compared to the use of an investiga-
tional drug in the usual studies under an Investigational
New Drug (IND) application, the EAP’s primary aim is
not to obtain information about the safety or effective-
ness of a drug [10]. The general criteria for an EAP are
that: patient(s) to be treated suffer from a serious or im-
mediately life-threatening disease for which there is no
comparable or satisfactory alternative therapy; and the
potential benefit justifies the potential risks of the use
and are not unreasonable in relation to the disease to be
treated [9].
There are three categories of EAP: for individual
patients, for intermediate-size patient populations and
for large populations of patients, who have no other
treatment option available, under a treatment protocol
or treatment IND application (see Table 1) [9].
In all categories of EAP the patients either cannot par-
ticipate or have already participated in a clinical trial for
the following reasons: patients have a different disease or
stage of disease or otherwise do not meet with the enrol-
ment criteria; enrolment in the trial is closed; and the trial
site is not geographically accessible. The FDA establishes
that early access to an investigational drug will not inter-
fere with clinical trials, since that is the most effective and
efficient way to establish whether the drug works and is
safe to use.
In Europe, EAP and CUP do not have the same meaning.
EMA identifies compassionate use to facilitate patients’
access to new treatment options under development for an
individual patient as Compassionate Use on a Named
Patient basis, or for a group of patients as CUPs [11].
The first is regulated by Article 5 of Directive 2001/83/
EC [12] defining the conditions under which physicians
can obtain, under their direct responsibility, an unauthor-
ised drug or a drug otherwise than for the authorised indi-
cations for individual patients with no on-label
therapeutic alternatives (see Table 2). The second is regu-
lated by Article 83 of Regulation (EC) No. 726/2004 [13],
which introduces the legal framework for the use of an
unauthorised drug (but eligible for being authorised
through the Centralised Procedure), for groups of patients
with life-threatening, long-lasting or seriously disabling
illnesses who currently cannot be treated satisfactorily
with authorised medicines, or who have a disease for
which no medicine has been authorised yet, or who are
not eligible for an ongoing clinical trial to obtain treat-
ment with a potentially life-saving medicine. The assump-
tions for compassionate use must be based on mature
randomised phase III trials or exploratory trials (e.g. un-
controlled phase II trials). The scientific data submitted
should permit assessment of the conditions for effective
and safe use of the medicinal product in a CUP. The com-
pany should ensure that patients taking part in a CUP
have access to the product during the period between the
granting of the centralised marketing authorisation and its
placement on the market [5].
The EMA permits companies that manufacture prom-
ising medicines to run CUPs to allow early access to
their medicine and to extend its use to patients who can
benefit from it. But EMA also permit that patients who
have been treated with the medicine during a clinical
trial and wish to continue using it may be able to do so
via an EAP [2].
EMA and FDA compassionate use definitions have the
same meaning. Conversely, the EMA definition of EAP
is similar to that of an Open-label Extension study.
In general, the European Medicines Agency’s Committee
for Medicinal Products for Human Use (CHMP) provides
the recommendations to all European Member States
(EuMS) on access to a medical product for unauthorised
indications, outside a clinical trial. The recommendations
complement national legislation, and do not replace it.
They also do not create any legal framework in the EuMSs.
The recommendations are optional, and are only imple-
mented by EuMSs that wish to implement them for their
patients [2, 5, 13].
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Table 1 Expanded Access Programme: comparison of definition
USA – Food and Drug Administration Europe – European Medicines Agency Italy – Ministerial Decree
A case-by-case basis for individual patients, including
for emergency useUnder this section, FDA may
permit an investigational drug to be used for the
treatment of an individual patient by a licensed
physician. The following characteristics must be
respected:
(1) The physician must determine that the probable
risk to the person from the investigational drug is
not greater than the probable risk from the disease
or condition
(2) FDA must determine that the patient cannot
obtain the drug under another Investigational
New Drug (IND) application or protocol
(3) Treatment is generally limited to a single course
of therapy for a specified duration unless FDA
expressly authorises multiple courses or chronic
therapy
(4) At the conclusion of treatment, the licensed
physician or sponsor must provide FDA with a
written summary of the results of the Expanded
Access use, including adverse effects
(5) When a significant number of similar individual
patient ExpandedAccess requests have been
submitted, FDA may ask the sponsor to submitan
IND or protocol for the use under an Expanded
Access for an intermediate-size patient population
or Expanded Access for larger group(s) of patients
under a treatment protocol or treatment IND
Moreover, the preamble to the proposed rule
stated that to support Expanded Access for an
individual patient when the patient has an
immediately life-threatening condition that is not
responsive to available therapy, ordinarily
completed phase 1 safety testing in humans at
doses similar to those to be used in the treatment,
together with preliminary evidence suggesting
possible effectiveness, would be sufficient to
support such use. However, the preamble further
stated that in some cases there may be no relevant
clinical experience, and the case for the potential
benefit may be based on preclinical data or on the
mechanism of action
An individual patient (Compassionate Use on a
Named Patient basis)The following characteristics
must be respected:
(1) A EU Member State (EuMS) may, in
accordance with legislation in force and to fulfil
special needs, authorise the use of a medicinal
product, otherwise than for the authorised
indications or the use of an unauthorised
medicinal product, supplied in response to a
bona fide unsolicited order, formulated by an
authorised health-care
professional for use by an individual patient
under his direct personal responsibility
(2) A EuMS may temporarily authorise the
distribution of an unauthorised medicinal product
in response to the suspected or confirmed spread
of pathogenic agents, toxins, chemical agents or
nuclear radiation, any of which could cause harm
(3) The doctor responsible for the treatment will
contact the manufacturer directly
In Italy, the therapeutic use of drugs
undergoing clinical trials outside a clinical
trial is permitted when there is no
comparable or satisfactory therapeutic
alternative for a severe pathology or rare
disease or condition that could be life-
threateningThe following characteristics must
be respected:
(1) The drug is already the subject of ongoing
or concluded phase III clinical trials for the
same specific therapeutic indication
(2) In specific cases of life-threatening conditions
, the drug is the subject of concluded phase II
clinical trials.The drug can be obtained by:
a. physician for an individual patient not treated
in a clinical trial;
b. several physicians working in different
centres or collaborative multicentre groups;
c. physicians or collaborative groups, for patients
who have participated in a clinical trial which has
shown effectiveness and tolerability profiles that
make it useful, for those who have participate in
the trial to exploit the results promptly
Intermediate-size patient populationUnder this
section, FDA may permit an investigational drug
to be used for the treatment of a patient
population (smaller than those typical of a
treatment IND or treatment protocol: 1–100
patients) with similar treatment needs who
otherwise do not qualify to participate in a
clinical trial. FDA may ask a sponsor to
consolidate Expanded Access under this section
when the agency has received a significant
number of requests for individual patient
Expanded Access to an investigational drug for
the same use. The following characteristics must
be respected:
(1) There is enough evidence that the drug is
safe at the dose and duration proposed for
Expanded Access use to justify a clinical trial of
the drug in the approximate number of patients
expected to receive the drug under Expanded
Access
(2) There is at least enough preliminary clinical
evidence of effectivenessof the drug, or of a
plausible pharmacologic effect of the drug, to
make Expanded Access use a reasonable
Group of patients (Compassionate Use
Programmes)According to Article 83, the aim of
this group is:
(1) To facilitate and improve the access of
patients in the EU to Compassionate Use
Programmes
(2) To favour a common approach regarding the
conditions of use, the conditions for distribution
and the patients targeted for the compassionate
use of unauthorised new medicinal products
(3) To increase transparency between EuMSs in
terms of treatment availabilityIt is applicable to:
a) Unauthorised medicinal products for human
use falling within the categories referred to in
Articles 3(1) and 3(2) of Regulation (EC) No. 726/
2004;
b) ‘'Patients with a chronically or seriously
debilitating disease, or a life-threatening disease,
and who cannot be treated satisfactorilya by
unauthorised medicinal product’ in the EU, or who
cannot enter a clinical trial;
c) Group of patientsb;
d) Medicinal product which is either ‘the subject
of an application for a centralised marketing
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Table 1 Expanded Access Programme: comparison of definition (Continued)
therapeutic option in the expected patient
population
(3) If the number of patients enrolled increases,
FDA may ask the sponsorto submit an IND or a
treatment protocolExpanded Access under this
section may be needed in the following
situations:
a) The drug is not being developed: for example,
because the disease or condition is so rare that
the sponsor is unable to recruit patients for
aclinical trial.
b) The drug is being studied in a clinical trial, but
patients are unable to participate in the trial
because they have a different disease or stage of
disease or otherwise do not meet the enrolment
criteria; because enrolment in the trial is closed,
or because the trial site is not geographically
accessible.
c) The drug is an approved product that is no
longer marketed for safety reasons or is
unavailable on the market due to failure to meet
the conditions of the approved application;
d) The drug contains the same active moiety as
an approved product that is unavailable on the
market due to failure to meet the conditions of
the approved application or a drug
shortageMoreover, the Expanded Access
submission must state whether the drug is being
developed or is not being developed and
describe the patient population to be treated.If
the drug is not being actively developed, the
sponsor must explain why the drug cannot
currently be developed for Expanded Access use
and under what circumstances the drug could
be developed. If the drug is being studied in a
clinical trial, the sponsor must explain why the
patients to be treated cannot be enrolled in the
clinical trial and under what circumstances the
sponsor will conduct a clinical trial in these
patients.
authorisation in accordance with Article 6 of
Regulation (EC) No. 726/2004 or is undergoing
clinical trials’ in the EU or elsewhereIt not is
applicable to:
a) Use of an unauthorised medicinal product for
Compassionate Use on a Named Patient basis
(as meant in Article 5 of Directive 2001/83/EC);
b) A medicinal product which has already been
authorised via the Centralised Procedure, even if
the proposed conditions of use and target
population are different from those of the
marketing authorisation;
c) Medicinal products which are not eligible for
the Centralised Procedure. Article 83 on
compassionate use is complementary to national
legislations and provides an option to MS who
wish to receive a CHMP opinion regarding the
conditions for compassionate use of a specific
medicinal product which falls within the scope of
Article 83.
Large populationsUnder this section, FDA may
FDA may permit an investigational drug to be
used for widespread treatment use. The
following characteristics must be respected:
(1) The drug is being investigated in a controlled
clinical trial under an IND designed to support a
marketing application for Expanded Access use, or
all clinical trials of the drug have been completed
(2) When the safety and potential effectiveness of
drug is known from ongoing or completed clinical
trials
(3) The sponsor is actively pursuing marketing
approval of the drug for Expanded Access use,
with due diligence
(4) When Expanded Access use is for a serious
disease or condition, there is sufficient clinical
evidence (phase 3 or completed phase 2 studies)
of safety and effectiveness to support Expanded
Access use
(5) When the Expanded Access use is for an
immediately life-threatening disease or condition,
the available scientific evidence (phase 3 or
completed phase 2 studies, but could be based on
more preliminary clinical evidence)
provides a reasonable basis to conclude that the
investigational drug may be effective and would not
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In Italy, access to an unauthorised drug or an
authorised drug not in accordance with the authorised
product information has been regulated by various
decrees (DLvo No. 648/1996, DLvo No. 94/1998, DLvo
No. 211/2003, Ministerial Decree 8 May 2003) [14–17].
The latter Ministerial Decree defines the terms of access
to an EAP (also called Early Access Programme) with
experimental drugs, outside a clinical trial, when there is
no comparable or satisfactory therapeutic alternative for
severe pathology or a rare disease or illness that could
be a life-threatening [14]. Access to such therapies is
possible if at least one of the following conditions is
met: the drug is already being tested in the same specific
therapeutic indication in ongoing or concluded phase III
or in concluded phase II clinical trials and the available
data must be sufficient to allow a positive judgment on
the effectiveness and the tolerability of the drug. The
supply of the drug can be requested by: a) the physician for
an individual patient not treated in a clinical trial; b) several
physicians working in different centres, or collaborative
multicentric groups; or c) physicians or collaborative
groups, for patients who have already participated in a
clinical trial with good effectiveness and tolerability profiles
where the results must be used promptly. Italian law has
adopted the EMA definition of EAP. Treatment data must
be collected as for observational studies and can be used as
‘support’ of the marketing authorisation dossier [14].
Worldwide Open-label Extension studies, defined as
clinical trials that follow a double-blind randomised
placebo-controlled trial phase IIB or IIIA, aim to generate
long-term data on the intervention efficacy, safety, toler-
ability and administration, and participants have the op-
tion of continuing treatment for an extended period [3].
Results from clinical trial records
In the considered period, 172 protocols were identified
through the OsSC:
 Twenty-one ‘EAPs’, of which 2 were for patients
with an available therapeutic alternative
 One hundred and fifty ‘Open-label Extension
studies’, of which 99 were coherent with study
definition, 49 were core studies that included the
extension in the study protocol and 2 were
extensions of another extension
 One ‘Other’ because it was registered as Extension
Study of EAP in the American Clinical Trials
Registry, while in the OsSC it was registered as an
Expanded Access Study
More than 50 % of the protocols concerned 3 thera-
peutic areas: nervous system diseases (30 %, 52/172),
oncology (12 %, 21/172) and immune system diseases
(12 %, 21/172). Almost all protocols (99 %) were multi-
centre with a median sample size of 780 patients, and
88 % (151/172) were international.
Focusing on the 21 EAPs, 52 % (11/21) had as their
primary endpoint ‘to give the possibility of early use of
the drug to patients who have no comparable or
Table 1 Expanded Access Programme: comparison of definition (Continued)
expose patients to an unreasonable and
significant risk of illness or injury
Expanded Access Programmes (EAPs)A company
that makes a promising medicine may choose to
run an EAP to allow early access to their
medicine and to widen its use to patients who
can benefit from it. For example, patients who
have been treated with the medicine during a
clinical trial and wish to continue treatment may
be able to do so via an EAP. These programmes
are often authorised by national authorities in
the same way as clinical trials, and patients are
followed in the same way as in a clinical trial
a’Patients who cannot be treated satisfactorily’ means patients left without treatment options or patients whose disease does not respond or relapses to available
treatments, or for whom the treatments are contraindicated or inadequate [11]
b’Group of patients’ can be interpreted as any set (i.e. more than one) of individual patients that would benefit from a treatment for a specific condition. The terms
‘cohort’, ‘collective use’, ‘patient group prescription’ or ‘special treatment programme’ used in some MSs, in accordance with national legislations, may correspond
with this concept [11]
CHMP Committee for Medicinal Products for Human Use, EC Ethic Committee, EU European Union, FDA Food and Drug Administration, MS member state
Table 2 Examples of use on a named patient basis
✓ The licensed form of a drug has been discontinued can be prescribed
on a named patient basis as it does not have a license
✓ The product is awaiting a license but is licensed elsewhere in the
world
✓ There is a local shortage or supply chain problems for an essential
medication
✓ Patients who have taken part in a clinical trial which has now ceased
can still be prescribed the ‘trial’ medication on a named patient basis if
it has been achieving good results
✓ There is a clinical need for an agent which is still in clinical trials and
the patient is not eligible for the trial, but it is felt they may benefit from
the drug
Specials prepared in a hospital pharmacy for individual patients, because
these items do not exist in a ready-made form
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satisfactory therapeutic alternative and cannot partici-
pate in the clinical trial’, while 43 % (9/21) presented a
primary endpoint of long-term safety and/or tolerability.
Almost all of the EAPs (95 %, 20/21) were sponsored by
pharmaceutical companies.
We encountered difficulties in classifying the study
protocols because in some cases (16 of 21) protocols
that have the purpose of providing the treatment to
patients who are not eligible for enrolment into a clinical
trials are presented as EAPs, in some cases (3 of 21)
studies that follow a clinical trial and include patients
who wish to continue the treatment are presented as
EAPs, in others cases (2 of 21) clinical trials are pre-
sented as EAPs. We also found EAPs classified as phase
II, III or IV clinical trials.
This is due to lack of a common definition of EAP:
European and Italian regulations provide the option to
include in an EAP patients who have been treated in a
clinical trial and wish to continue treatment; however,
for the FDA the EAP guarantees treatment to patients
who cannot participate in a clinical trial, while partici-
pants in a clinical trial have the option to enter an
Open-label Extension study, not an EAP.
Tables 3, 4 and 5 present 3 case-models showing the
consequences of this lack of harmonisation. In all cases
the EAPs are managed like clinical trials, they are regis-
tered in OsSC and/or Clinicaltrials.gov and/or other trial
registries, but without following the rules for clinical trials;
for example, the sponsor is not available to cover the costs
of drugs in the add-on therapy of the experimental arm.
Discussion
This study shows how the definition of EAP is not the
same all over the world. The comparison of the USA,
European and Italian regulations highlights several simi-
larities and differences.
Regarding the similarities:
 The patient must have a life-threatening, long-
lasting or seriously disabling illness
 The patient has no comparable or satisfactory
alternative on-label therapy
 The aim of an EAP is to simplify the therapeutic use
of an unauthorised drug (or of an authorised drug
for indication unauthorised) outside a clinical trial
 The data on clinical trials (and pre-clinical trial for
FDA case-by-case) must be sufficient to permit a
positive judgment on the efficacy and tolerability of
the drug
 EAPs cannot be used for investigational purposes or
commercial pre-authorisation activities
 EAPs regard individual patients or groups of
patients
There are, then, some significant differences:
 FDA (a) defines as EAP (also called CUP) the access
protocols for experimental pharmacological
therapies outside a clinical trial; (b) these protocols
are applied for individual patients, intermediate-size
patient populations and large populations; and (c)
the patients who can participate in clinical trials are
excluded
 EMA (a) defines the access protocols to
experimental pharmacological drugs outside a
clinical trial as a CUP and Compassionate Use on a
Named Patient basis; (b) these protocols are applied
for groups of patients or individuals, respectively
EAPs represent for EMA a way to continue the treat-
ment for a patient who has been treated with a drug
during a clinical trial
 In Italy (a) the therapeutic use of an investigational
drug outside a clinical trial is defined as an EAP
(also called Early Access Programme); (b) the EAP
Table 3 CASE MODEL 1: Example of protocols of EAP that have the purpose of providing the treatment to patients who are not
eligible for enrolment into a clinical trials.
Case model 1 Therapeutic area: Neoplasia















Progressive disease after treatment
with marketed drugs or intolerance
Secondary: assess progression-free
and overall survival
Patients not previously treated with the experimental
drug (who has not participated in a clinical trial)
In this case-model, patients included in the protocol have no comparable or satisfactory therapeutic alternatives but the protocol has safety and tolerability
primary endpoints
Considerations: this protocol (on the basis of the target), can come under Ministerial Decree 8 May 8 2003, as a CUP and EAP, because it ensures access to
investigational drugs for patients who have no comparable or satisfactory therapeutic alternatives. However, the primary endpoint is typical of a clinical trial
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involves both individuals and groups; and (c)
patients who have already participated in a clinical
trial and need to use the randomised controlled trial
(RCT) results quickly are included
Therefore, in the USA the EAP has just a therapeutic
endpoint, whereas for European and Italian regulations
the EAP could also have efficacy and/or safety endpoints.
EAP versus Open-label Extension studies
The FDA regulation clearly distinguishes EAP and
Open-label Extension studies [1], whereas this is not
clear at all for European and Italian regulations [2, 14].
For the latter, patients who have been treated with the
investigational drug during a clinical trial can enter
an EAP or an Open-label Extension study as well.
However, in an Open-label Extension study all patients
who have participated in the study core (experimental and
control arm) have access to the experimental treatment.
Instead, in an EAP only patients who have been treated
with the investigational drug (not the control arm) during
a clinical trial can continue treatment [18]. This lack of a
clear distinction generates misunderstandings.
For European and Italian regulations, the studies defined
as EAPs (also called Early Access Programmes) could have
scientific endpoints as Open-label Extension studies. This is
possible because EMA recommendations presuppose that
safety data can also be collected during CUPs [12] and the
Italian Ministerial Decree 8 May 2003 provides for the use
of the data obtained from EAPs in ‘support’ of the market-
ing authorisation dossier [14]. FDA regulation, on the other
hand, excludes the fact that the primary intention of
Expanded Access uses is to obtain information about the
safety or effectiveness of a drug, and also excludes the fact
that the data obtained from EAPs can interfere with the au-
thorisation procedure for a new drug [19].
Furthermore, in Italy for EAPs (also called Early
Access Programmes) the sponsor is not open to covering
the costs of standard care, any add-on therapy and man-
aging it as an Open-label Extension study which imposes
a part of the cost on the trial centre.
EAP versus clinical trials
According to all examined regulations, wherever the
physician directing the treatment starts an EAP he
must sign up as the clinical investigator/s and submit
to the EC and to the competent authority (e.g. AIFA in
Italy) a study protocol including and adequately docu-
menting the following:
 The rationale for the intended use of the drug
 The criteria for patient selection
 The available data on the quality, safety and efficacy
of the medicinal product
 The scientific data submitted should allow an
assessment of whether the drug is reasonably safe at
Table 4 CASE MODEL 2: Example of protocols of EAP that follow a clinical trial and include patients who wish to continue the
treatment
Case model 2 Therapeutic area: Urogenital diseases





Patients who have participated in the clinical trial
and need prompt access to the results
Primary: assess the safety and




In this case-model, patients included in the protocol have no comparable or satisfactory therapeutic alternatives but they have participated in the clinical trial and
need to continue the treatment
Considerations: despite the protocol target being coherent in Italy and in Europe with the EAP, the primary endpoint is typical of a clinical trial and the sponsor
manages the protocol as if it were a clinical trial. In the USA this protocol would have be configured as an Open-label Extension study
Table 5 CASE MODEL 3: Example of clinical trial who is presented as EAPs
Case model 3 Therapeutic area: Viral diseases
Clinical study
design






Patients with chronic hepatitis C, acute fibrosis and cirrhosis Primary: make possible early use of the
drug for patients who cannot participate
in the clinical trial
International Phase
3
Patients with similar features to those in the clinical trial but
unable to participate because the trial is closed or the trial
site is not geographically accessible, or because not eligible
under ongoing trial protocols
Secondary: assess the safety and
tolerability of the treatment
In this case-model, patients included in the protocol have no comparable or satisfactory therapeutic alternative and they cannot participate in the clinical trial
Considerations: since the purpose of the protocol is to make possible early use of the drug for patients who have no comparable or satisfactory therapeutic
alternative and cannot participate in the clinical trial, this protocol can come under Ministerial Decree 8 May 2003 [14], as a CUP [11] and EAP [21]. However, the
study is managed like a clinical trial, and the cost of the add-on therapy is charged to the centre where the trial takes place
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the dose and duration proposed for the intended
target population
 Patients who enter in an EAP must all sign an
Informed Consent Form
These criteria are the same for phase II and III clinical
trials and it is probably for this reason that sponsors may
wrongly interpret EAPs as clinical trials, although 1) FDA
and EMA point out: ‘patients should always be considered
for inclusion in a clinical trial before being offered
programmes outside the clinical trial’ [2]; 2) data collec-
tion on safety and efficacy is the primary objective of a
clinical trial [20–23]; and 3) only clinical trials can be gen-
erally recognised as a ‘scientifically valid and reliable’ way
to provide safety and efficacy data transferable on the gen-
eral population. In other words, ‘From a methodological
point of view, clinical trials are practically the only means
to obtain reliable and interpretable efficacy and safety
data for a medicinal product’ [4].
The problem is that according to European regulation,
‘The use of drug outside to clinical trial is often
authorised by national authorities in the same way as
clinical trials, and patients are followed in the same way
as patients in a clinical trial’ [2, 24, 25].
Therefore, there should be a clear distinction between
EAPs and clinical trials: a protocol designed to provide
for an early access drug (therapeutic endpoint), when
there is no comparable or satisfactory therapeutic alter-
native, should be clearly distinguished from a clinical
trial whose aim is to assess the safety and efficacy of in-
vestigational drugs (scientific endpoint).
To clearly define ‘the rules of the game’, the intervention
of regulatory agencies would be necessary. Normally,
EAPs are conducted in parallel with the drug clinical trials
or when the drug is already under assessment for market-
ing authorisation by a competent authority, or prior to its
launch. As such, EAPs may be initiated as early as phases
II/III, but can start at any time during the approval
process or after being granted a market authorisation but
prior to market launch, a period which may cover 1 to 2
years. As sufficient safety and efficiency data is needed for
the approval of these programmes, application is more
feasible late in the drug development. However, under ex-
ceptional circumstances, drugs may obtain early access
with very little clinical information such as for Ebola or
H1N1 pandemic risk.
Conclusions
While the FDA definition of EAPs is very clear, the
EMA definition of EAPs is similar to the definition of
Open-label Extension studies. The internationalisation
of the studies requires a harmonisation on a global level
of legislation and correct/clear definition to eliminate
misclassification of study protocols. As a consequences
of misclassification, it is possible to find an EAP with an
efficacy or safety endpoint or an EAP managed as a
clinical trial or EAPs classified in the trial registries as
phase II, III or IV clinical trials.
To avoid misclassification the authors suggest that: a)
EMA definition should be harmonised starting from the
FDA definition; and b) European regulation should not
be optional but it should be adopted compulsorily by na-
tional regulations. Moreover, separate registries for both
EAP and clinical trials could give researchers/clinicians
and patients a better understanding of the situation in
which they are receiving the drug, they are not in a clinical
trial and they are not receiving a treatment expected ‘from
normal clinical practice’. Separated registry could allow
simplification of protocol assessment by the authorities
and national ECs and it could also exclude the fact that ef-
ficacy data obtained from EAPs are used by the sponsors
for registration purposes because data obtained from
EAPs should not interfere [14, 20] with the authorisation
procedure for a new drug but should increase information
for pharmacovigilance plans.
To protect patients, European legislation needs to be
more explicit and informative with regard to the regula-
tory requirements, restrictions, and responsibilities in
EAPs. EAPs and clinical trials must be separated,
firstly to protect patients from exploitation, and sec-
ondly so that both the needs of the seriously ill and
those of society can best be served [6].
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